In a pan-cancer BRAF basket study, vemurafenib showed marked activity in BRAF-mutant lung and other tumors but not in colorectal cancer, revealing lineage-dependent signaling differences [115,119]. This evidence concerns the gene BRAF and colorectal cancer.